Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China
Cosmos Health is Forcing the Market to Reframe the Conversation
1933 Industries Issues Reminder to Debenture Holders Ahead of December 22 Conversion Deadline and Highlights Positive Industry Developments
Remedy’s Nutrition® Launches Mega VMT™ High-Potency Multivitamin to Revolutionize Daily Energy and Nutritional Wellness
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company’s Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
Upon closing, Eric M. Jackson to Lead Combined Company as Chief Executive Officer and ChairmanNORTH PALM BEACH, Fla., Dec. 16,...
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025...
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025...
Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025...
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence...
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),...
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),...
TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),...
Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 16, 2025...
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16,...
